Cytokine-like protein 1–induced survival of monocytes suggests a combined strategy targeting MCL1 and MAPK in CMML

Margaux Sevin; Franck Debeurme; Lucie Laplane; Séverine Badel; Margot Morabito; Hannah Newman; Miguel Torres‐Martín; Qin Yang; Bouchra Badaoui; Orianne Wagner‐Ballon; Véronique Saada; Dorothée Selimoglu‐Buet; Laurence Kraus‐Berthier; Sébastien Banquet; Alix Derréal; Pierre Fenaux; Raphaël Itzykson; Thorsten Braun; Gabriel Étienne; Céline Berthon; Sylvain Thépot; Oliver Kepp; Guido Guido Kroemer; Eric Padron; María E. Figueroa; Nathalie Droin; Éric Solary

doi:10.1182/blood.2020008729

Related publications

Article2002

Inhibition of p38 MAPK by Glucocorticoids via Induction of MAPK Phosphatase-1 Enhances Nontypeable Haemophilus influenzae-induced Expression of Toll-like Receptor 2

Akira Imasato, Christèle Desbois‐Mouthon, Jiahuai Han, Hirofumi Kai, Andrew C.B. Cato, Akira Shizuo, Jian‐Dong Li

Journal of Biological Chemistry

Article2006

Protein kinase C zeta plays an essential role for Mycobacterium tuberculosis-induced extracellular signal-regulated kinase 1/2 activation in monocytes/macrophages via Toll-like receptor 2

Chul–Su Yang, Ji‐Sook Lee, Chang‐Hwa Song, Gang Min Hur, Sung Joong Lee, Sakae Tanaka, Akira Shizuo, Tae-Hyun Paik, Eun‐Kyeong Jo

Cellular Microbiology

Article1995

Corticosteroid inhibition of macrophage inflammatory protein-1 alpha in human monocytes and alveolar macrophages

Neville Berkman, P J Jose, Tom A. Williams, Thomas J. Schall, Peter J Barnes, Kian Fan Chung

Article2018

Reversal of Aging‐Induced Increases in Aortic Stiffness by Targeting Cytoskeletal Protein‐Protein Interfaces

Christopher Nicholson, Kuldeep Singh, Robert J. Saphirstein, Yuan Gao, Qian Li, Joanna Chiu, Paul C. Leavis, Germaine C. Verwoert, Gary F. Mitchell, Tyrone M. Porter, Kathleen G. Morgan, Kirill V. Tarasov, Aaron Isaacs, Albert V. Smith, Yasmin Yasmin, Ernst Rietzschel, Toshiko Tanaka, Yongmei Liu, Afshin Parsa, Samer S. Najjar, Kevin M. O’Shaughnessy, Sigurður Sigurðsson, Marc De Buyzere, Martin G. Larson,

Article2022

Targeting wild-type TP53 using AMG 232 in combination with MAPK inhibition in Metastatic Melanoma; a phase 1 study

Stergios J. Moschos, Shahneen Sandhu, Karl D. Lewis, Ryan J. Sullivan, Igor Puzanov, Douglas B. Johnson, Haby Henary, Hansen Wong, Vijay Upreti, Georgina V. Long, Keith T. Flaherty